Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-814-0 | CAS number: 88-24-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 3 October 2016 to 4 January 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- 6,6'-di-tert-butyl-4,4'-diethyl-2,2'-methylenediphenol
- EC Number:
- 201-814-0
- EC Name:
- 6,6'-di-tert-butyl-4,4'-diethyl-2,2'-methylenediphenol
- Cas Number:
- 88-24-4
- Molecular formula:
- C25H36O2
- IUPAC Name:
- 2-tert-butyl-6-[(3-tert-butyl-5-ethyl-2-hydroxyphenyl)methyl]-4-ethylphenol
- Test material form:
- solid: particulate/powder
Constituent 1
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- other: CBA/CaOlaHsd
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Envigo - San Pietro al Natisone (UD) - Zona Industriale Azzida, 57, 33049 Italy
- Females nulliparous and non-pregnant: yes
- Microbiological status of animals, when known: SPF at arrival
- Age at study initiation: 10 weeks old (age-matched, within one week) 1
- Weight at study initiation: 20.2 – 22.3 grams (The weight variation in animals in the study did not exceed ± 20 % of the mean weight.)
- Housing: Group caging (Type II. polypropylene / polycarbonate)
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 21 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18.1 - 25.7°C
- Humidity (%): 23 - 84 %
- Air changes (per hr): 15-20 air exchanges/hour
- Photoperiod (hrs dark / hrs light): 12 hours daily, from 6.00 a.m. to 6.00 p.m.
- IN-LIFE DATES: From: November 02 2016 (start treatment) To: November 8, 2016
Study design: in vivo (LLNA)
- Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- 0, 5, 10, 25 and 50%
- No. of animals per dose:
- 4 animals per dose
- Details on study design:
- PRE-SCREEN TESTS:
The Preliminary Irritation/Toxicity Test was started according to the Study Plan on CBA/CaOlaHsd mice using two doses (2 animals/dose) at test item concentrations of 50% (w/v) and 25 % (w/v) in AOO. The preliminary experiment was conducted in a similar experimental manner to the main study, but it was terminated on Day 6 and the radioactive
proliferation assay was not performed. Based on the observation of the solubility test, the maximum available concentration was 50 % (w/v).
No mortality or signs of systemic toxicity were observed. Minimal amount of test item precipitate was observed for both animals of the 50% (w/v) dose group on Days 1-4 or Days 1-2. There were no indications of any irritancy at the site of application. Marked body weight loss (>5% reduction of body weight) was observed for both animals of the 50% (w/v) dose group, the mean body weight loss of the 50% (w/v) group was more than 5%.
Ear thickness of the animals was measured using by a thickness gauge on Days 1, 3 and 6, and by ear punch weight determination after the euthanasia of the experimental animals on
Day 6. The ear thickness values and ear punch weights were within the acceptable range.
The draining auricular lymph nodes of the animals were visually examined: they were normal in both dose groups (subjective judgement by analogy with observations of former
experiments). Based on these results, 50% (w/v) dose was selected as top dose for the main test.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: Local Lymph Node Assay
- Criteria used to consider a positive response: Desintegration per minutes (DPM) was measured for each pooled group of nodes. The measured DPM values were corrected with the background DPM value (“DPM”). The average of the two measured DPM values of 5 % (w/v) TCA solutions was used as background DPM value. The results were expressed as “DPN” (DPM divided by the number of lymph nodes) following the industry standard for data presentation.
Stimulation index (SI = DPN value of a treated group divided by the DPN value of the negative control group) for each treatment group was also calculated. A stimulation index of 3 or greater is an indication of a positive result.
TREATMENT PREPARATION AND ADMINISTRATION:
During the study, animals were topically dosed with 25 μL of the appropriate formulation using a pipette on the dorsal surface of each ear. Each animal was dosed once a day for three consecutive days (Days 1, 2 and 3). There was no treatment on Days 4, 5 and 6.
On Day 6, animals were taken to the radioactive suite and each mouse was intravenously injected via the tail vein with 250 μL of sterile PBS (phosphate buffered saline) containing approximately 20 μCi of 3HTdR using a gauge 25G x 1" hypodermic needle with 1 mL sterile syringe. Once injected, the mice were left for 5 hours (± 30 minutes).
Five hours (± 30 minutes) after intravenous injection the mice were euthanized by asphyxiation with ascending doses of carbon dioxide and the draining auricular lymph nodes were excised. Once removed, the nodes of mice from each test group was pooled and collected in separate Petri dishes containing a small amount (1-2 mL) of PBS to keep the nodes wet before processing.
A single cell suspension (SCS) of pooled lymph node cells (LNCs) was prepared and collected in disposable tubes by gentle mechanical disaggregating of the lymph nodes through a cell strainer using the plunger of a disposable syringe. The cell strainer was washed with PBS (up to 10 mL).
After the final washing step, supernatants were removed. Pellets were gently agitated resuspended and 3 mL of 5 % (w/v) TCA solution was added to the tubes for precipitation of macromolecules at 2-8°C overnight.
After a last centrifugation, pellets were resuspended in 1 mL of 5 % (w/v) TCA solution and dispersed by using an ultrasonic bath. Samples were transferred into a suitable sized scintillation vial filled with 10 mL of scintillation liquid and thoroughly mixed. The vials were loaded into a β-scintillation counter and 3HTdR incorporation was measured (10-minute measurement).
The β-counter expresses the 3HTdR incorporation as the number of radioactive disintegrations per minute (DPM). Background level was also measured in duplicates by adding 1 mL of 5 % (w/v) TCA solution into a scintillation vial filled with 10 mL of scintillation liquid. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- According to the OECD guideline 429, a statistical analysis of the data is not mandatory.
Results and discussion
- Positive control results:
- The positive control substance was examined at a concentration of 25 % in the relevant vehicle (AOO) using CBA/CaOlaHsd mice.
No mortality, cutaneous reactions or signs of toxicity were observed for the positive control substance in the study. A lymphoproliferative response in line with historic positive control data (stimulation index value of 7.8) was noted for HCA in the main experiment. This value was considered to confirm the appropriate performance of the assay.
In vivo (LLNA)
Resultsopen allclose all
- Parameter:
- other: DPN
- Value:
- 354.8
- Test group / Remarks:
- Negative control
- Parameter:
- other: DPN
- Value:
- 169.9
- Test group / Remarks:
- 50 (w/v)%
- Parameter:
- other: DPN
- Value:
- 239.3
- Test group / Remarks:
- 25(w/v)%
- Parameter:
- other: DPN
- Value:
- 273.9
- Test group / Remarks:
- 10 (w/v)%
- Parameter:
- other: DPN
- Value:
- 387
- Test group / Remarks:
- 5 (w/v)%
- Key result
- Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- Negative control
- Key result
- Parameter:
- SI
- Value:
- 0.5
- Test group / Remarks:
- 50 (w/v)%
- Key result
- Parameter:
- SI
- Value:
- 0.7
- Test group / Remarks:
- 25 (w/v)%
- Key result
- Parameter:
- SI
- Value:
- 0.8
- Test group / Remarks:
- 10 (w/v)%
- Parameter:
- SI
- Value:
- 1.1
- Test group / Remarks:
- 5 (w/v)%
- Cellular proliferation data / Observations:
- PROLIFERATION ASSAY
The appearance of the lymph nodes was normal in the negative control group and in all the test item treated dose groups.
Larger than normal lymph nodes were observed in the positive control group.
The stimulation index values were 0.5, 0.7, 0.8 and 1.1 at concentrations of 50% (w/v), 25% (w/v), 10% (w/v) and 5 % (w/v), respectively.
CLINICAL OBSERVATION
No mortality or signs of systemic toxicity were observed during the study. Test item precipitate or minimal amount of test item precipitate was observed for all animals of the
50% (w/v) dose group on Days 2-3. There were no indications of any irritancy at the site of application.
BODY WEIGHT MEASUREMENT
No marked body weight loss (>5% reduction of body weight) was observed.
INTERPRETATION OF OBSERVATIONS
The test item was solid, which was formulated in AOO. Since there were no confounding effects of irritation or systemic toxicity at the applied concentrations, the proliferation values obtained are considered to reflect the real potential of the test item to cause lymphoproliferation in the Local Lymph Node Assay. The resulting stimulation indices observed under these exaggerated test conditions was considered to be good evidence that 6,6’-di-tert-butyl-4,4’-diethyl-2,2’-methylenediphenol is a non-sensitizer. The size of lymph nodes was in good correlation with this conclusion. Based on the observed results, the test item does not need classification according to the GHS or CLP.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of the present assay 6,6’-di-tert-butyl-4,4’-diethyl-2,2’-methylenediphenol was shown to have no sensitisation potential (non-sensitizer) in the Local Lymph Node Assay.
- Executive summary:
The objective of the study was to determine the skin sensitisation potential of 6,6’-di-tert-butyl-4,4’-diethyl-2,2’-methylenediphenol following dermal exposure. The study was performed with vertebrate animals as no full regulatory in vitro alternative was available at time of study initiation. The minimum number of animals was used, corresponding to the regulatory guidelines being followed.
Based on the results of the preliminary compatibility test, the test item characteristics, its usage and on the recommendations of the OECD Guideline, the test item was tested for formulation compatibility in AOO (acetone:olive oil 4:1 (v:v) mixture). The highest achievable concentration based on the regulatory requirements of the OECD guideline and the physical characteristics of the test item was 50% (w/v).
The preliminary irritation/toxicity test was performed in CBA/CaOlaHsd mice using two doses (2 animals/dose): 50% (w/v) and 25% (w/v) in AOO. Based on the observations recorded in the preliminary test, the 50% (w/v) was selected as top dose for the main test. In the main assay, twenty four female CBA/CaOlHsd mice were allocated to six groups of four animals each:
- four groups received 6,6’-di-tert-butyl-4,4’-diethyl-2,2’- methylenediphenol (formulated in AOO) at 50% (w/v), 25% (w/v), 10% (w/v) and 5% (w/v) concentrations
- the negative control group received the vehicle (AOO),
- the positive control group received 25% (w/v) HCA (dissolved in AOO).
The test item solutions were applied on the dorsal surface of ears of experimental animals (25 µL/ear) for three consecutive days (Days 1, 2 and 3). There was no treatment on Days 4, 5 and 6. The cell proliferation in the local lymph nodes was measured by incorporation of tritiated methyl thymidine (3HTdR) and the values obtained were used to calculate stimulation indices (SI).
No mortality or signs of systemic toxicity were observed during the study. There were no indications of any irritancy at the site of application on the experimental animals. No marked body weight loss (≥ 5%) was observed on the mean body weight changes. The stimulation index values were 0.5, 0.7, 0.8 and 1.1 at concentrations of 50% (w/v), 25% (w/v), 10% (w/v) and 5 % (w/v), respectively.
The result of the positive control substance α-Hexylcinnamaldehyde (HCA) dissolved in the same vehicle was used to demonstrate the appropriate performance of the assay. A lymphoproliferative response in line with historic positive control data was noted for the positive control chemical, this result confirmed the validity of the assay.
In conclusion, under the conditions of the present assay, 6,6’-di-tert-butyl-4,4’-diethyl-2,2’-methylenediphenol, tested in a suitable vehicle, was shown to have
no sensitisation potential (non-sensitizer) in the Local Lymph Node Assay. No classification is triggered according to Regulation (EC) No 1272/2008 (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.